Skip to main content

Table 2 Clinical characteristics of systemic lupus erythematosus patients according to global disease activity (n = 73)

From: The Fatigue Assessment Scale as a simple and reliable tool in systemic lupus erythematosus: a cross-sectional study

  Inactive SLE (n = 50) Active SLE (n = 23) p value§
Age, median (IQR) years 46 (35–59) 39 (30–52) 0.20
Female sex (%) 44 (88) 21 (91) 0.68
Caucasian, no. (%) 38 (76) 18 (78) 0.83
Higher education*, no./total (%) 20/39 (51) 10/20 (50) 0.93
Active smoker, no. (%) 9 (18) 8 (35) 0.12
Body mass index, median (IQR) 24 (20–29) 22 (19–24) 0.35
Use of psychiatric medication£, no. (%) 9 (18) 5 (22) 0.75
Disease duration, median (IQR) years 7 (3–15) 6 (3–15) 0.42
History of lupus nephritis, no (%) 19 (38) 6 (26) 0.31
History of neurolupus, no (%) 6 (12) 2 (7) 0.67
SELENA-SLEDAI, median (IQR) score 2 (0–2) 6 (4–10) < 0.001
PGA score, median (IQR) score 0 (0–0) 1 (1–2) < 0.001
Immunomodulators past month, no. (%) 44 (88) 20 (87) 0.90
 Antimalarials, no. (%) 37 (74) 15 (65) 0.44
 Systemic corticosteroids, no. (%) 26 (52) 13 (57) 0.72
 Immunosuppressants, no. (%) 25 (50) 10 (43) 0.60
  1. IQR interquartile range, SLE systemic lupus erythematosus
  2. *Active disease is defined as a Systemic Lupus Erythematosus Disease Activity Index score with the Safety of Estrogens in Lupus Erythematosus National Assessment modification (SELENA-SLEDAI) ≥ 4 and a Physician’s Global Assessment score (PGA) ≥ 1
  3. £Defined as any antidepressants, antipsychotics, and anxiolytics/hypnotics
  4. §p value < 0.05 is considered significant